Canada vs Egypt: HIV/AIDS deaths averted by antiretroviral therapy
Canada
1,943 deaths
in 2022
Egypt
2,035 deaths
in 2024
Canada rank
59th
Egypt rank
56th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Canada
- Egypt
How they compare
Egypt currently reports 2,035 deaths against 1,943 deaths in Canada, a difference of 92 deaths.
The two have swapped places 1 time across 33 shared years of data; in 1990 it was Egypt ahead.
Canada ranks 59th and Egypt ranks 56th of 157 countries.
Canada has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Canada | Egypt | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 433.39 deaths | 0 deaths | 433.39 deaths | Canada |
| 2000s | 1,530 deaths | 23.89 deaths | 1,506 deaths | Canada |
| 2010s | 2,092 deaths | 346.74 deaths | 1,745 deaths | Canada |
| 2020s | 2,002 deaths | 1,213 deaths | 788.42 deaths | Canada |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Canada or Egypt?
- Egypt, at 2,035 deaths against 1,943 deaths in Canada as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Canada and Egypt?
- 92 deaths, with Egypt ahead.
- How many years of comparable data are there for Canada and Egypt?
- 33 years are reported by both, from 1990 to 2022.
- How do Canada and Egypt rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Canada ranks 59th and Egypt ranks 56th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.